Validated COuGH RefleX Score Can Predict Likelihood of GERD
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 6, 2024 -- The validated Cough, Overweight/Obesity, Globus, Hiatal Hernia, Regurgitation, and Male Sex (COuGH RefluX) score can predict the likelihood of proven gastroesophageal reflux disease (GERD) in patients with chronic laryngeal symptoms, according to a study published online Feb. 1 in Clinical Gastroenterology and Hepatology.
Amanda J. Krause, M.D., from the University of California San Diego in La Jolla, and colleagues conducted a multicenter international study involving adults with chronic laryngeal symptoms who underwent objective testing (upper gastrointestinal endoscopy and/or ambulatory reflux monitoring) between March 2018 and May 2023. A model with optimal receiver operating characteristic curves was identified in the training phase, and β coefficients informed a weighted model. Performance characteristics of the weighted model were assessed in the validation phase. Overall, 304 adults were included in the training cohort and 552 in the validation cohort.
The researchers found that the optimal predictive model was the COuGH RefluX score (area under the curve, 0.68), with a lower and upper threshold of 2.5 and 5.0, respectively, for predicting proven GERD. The COuGH RefluX score had an area under the curve of 0.67 in the validation phase, with sensitivity and specificity of 79 and 81 percent, respectively, for proven GERD.
"The score can be used, in conjunction with other noninvasive testing, to help guide diagnostic strategies to reduce inappropriate protein pump inhibitor use and testing for patients referred for laryngopharyngeal reflex evaluation," the authors write.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.